Extracorporeal therapy in sepsis: Are we there yet

Kidney International

Volumn 81, Issue 4, 2012, Pages 336-338

  Shukla, Ashutosh M ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADSORBENT; CYTOSORB; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADSORPTION; CYTOKINE RELEASE; DISEASE SEVERITY; EXTRACORPOREAL THERAPY; HEMOFILTRATION; HUMAN; IMMUNOREGULATION; INFLAMMATION; INTENSIVE CARE; MEDICAL PROCEDURES; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SIGNAL TRANSDUCTION; THERAPY EFFECT;

EID: 84856507269     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.375     Document Type: Note

References (15)

1. Tetta C , Bellomo R , Inguaggiato P et al. Endotoxin and cytokine removal in sepsis. Ther Apher 2002; 6: 109-115. (Pubitemid 34507300)
2. Simmons EM , Himmelfarb J , Sezer MT et al. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int 2004; 65: 1357-1365. (Pubitemid 38406974)
3. Marshall JC. Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov 2003; 2: 3 91-4 05. (Pubitemid 37361709)
4. McMaster P , Shann F. The use of extracorporeal techniques to remove humoral factors in sepsis. Pediatr Crit Care Med 2003; 4: 2-7.
5. Ronco C , Bonello M , Bordoni V et al. Extracorporeal therapies in non-renal disease: treatment of sepsis and the peak concentration hypothesis. Blood Purif 2004; 2 2: 1 64-1 74. (Pubitemid 38142302)
6. Peng Z-Y , Wang H-Z , Carter MJ et al. Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsis. Kidney Int 2012; 8 1: 363-369.
7. Courtine E , P ène F , Cagnard N et al. Critical role of cRel subunit of NF- B in sepsis survival. Infect Immun 2011; 7 9: 1 848-1 854.
8. Dejager L , Pinheiro I , Dejonckheere E , Libert C. Cecal ligation and puncture: the gold standard model for polymicrobial sepsis? Trends Microbiol 2011 198-208.
9. De Vriese AS , Colardyn FA , Philipp é JJ et al. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999; 10: 846-853. (Pubitemid 29149536)
10. Vernon DD , Sherbotie JR. Continuous renal replacement therapy for systemic inflammatory response syndrome: not today. Pediatr Crit Care Med 2010; 1 1: 7 63-7 64.
11. Payen D , Mateo J , Cavaillon JM et al. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med 2009; 37: 803-810.
12. Cole L , Bellomo R , Journois D et al. High-volume haemofiltration in human septic shock. Intensive Care Med 2001; 2 7: 9 78-9 86. (Pubitemid 32662478)
13. de Pont AC. Hemofiltration in the early phase of sepsis: friend or foe? Crit Care Med 2009 37 1125-1126.
14. Murray PT , Liu KD. Acute kidney injury and critical care nephrology. N ephrol Self Assess Program 2011; 10: 242-246.
15. Cruz DN , Antonelli M , Fumagalli R et al. Early use of polymyxin B hemoperfusion in abdominal septic shock. J AMA 2009; 301: 2 445-2 452.